



HAL
open science

Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD

Eleonora Latis, David Michonneau, Claire Leloup, Hugo Varet, Régis Peffault de Latour, Elisabetta Bianchi, Gérard Socié, Lars Rogge

► **To cite this version:**

Eleonora Latis, David Michonneau, Claire Leloup, Hugo Varet, Régis Peffault de Latour, et al.. Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD. *Blood Advances*, 2020, 4 (16), pp.3927-3942. 10.1182/bloodadvances.2019001032 . pasteur-02918738

HAL Id: pasteur-02918738

<https://pasteur.hal.science/pasteur-02918738>

Submitted on 21 Aug 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD

Eleonora Latis,^{1,2,*} David Michonneau,^{3,4,*} Claire Leloup,^{1,*} Hugo Varet,⁵ Régis Peffault de Latour,^{3,4} CRYOSTEM Consortium, Elisabetta Bianchi,¹ Gérard Socié,^{3,4,†} and Lars Rogge^{1,†}

¹Immunoregulation Unit, Department of Immunology, Institut Pasteur, Paris, France; ²Université Paris Diderot, Sorbonne Paris Cité, Paris, France; ³Hematology Transplantation, Assistance Publique-Hôpitaux de Paris, Saint Louis Hospital, Paris, France; ⁴INSERM U976, Université de Paris, Paris, France; and ⁵Hub de Bioinformatique et Biostatistique, Département Biologie Computationnelle, USR 3756 CNRS, Institut Pasteur, Paris, France

Key Points

- CD4⁺ and CD8⁺ T cells with a T memory stem cell-like phenotype are expanded at the onset of aGVHD.
- Molecular profiles of T cells at aGVHD onset are characterized by decreased TGF- β and increased NF- κ B signaling.

The cellular and molecular processes involved in acute graft-versus-host disease (aGVHD) development early after allogeneic hematopoietic cell transplantation (HCT) in humans remain largely unknown. We have performed multiparameter immunophenotyping and molecular profiling of CD4⁺ and CD8⁺ T cells in 2 independent cohorts of patients undergoing HCT, as well as in their HLA-identical sibling donors. Cellular profiling using spectral flow cytometry showed an incomplete reconstitution of the T-cell compartment in recipients without aGVHD early after transplantation, as well as a shift toward an effector memory phenotype, paralleled by depletion of the naive T-cell pool. Molecular profiling of T-cell populations in donors vs recipients without aGVHD revealed increased pathway activity of >40 gene modules in recipients. These pathways were associated in particular with T-cell activation, adhesion, migration, and effector functions. Cellular profiles from recipients developing aGVHD displayed an enrichment of cells with a T memory stem cell-like phenotype compared with recipients without aGVHD. Comparison of gene profiles from these recipients revealed that transforming growth factor- β (TGF- β) signaling was most significantly downregulated, whereas the pathway activity of NF- κ B-associated transcription factors and signaling pathways were increased, at aGVHD onset. This study suggests that the integration of cellular and molecular profiles provides new insights into the development of aGVHD in humans.

Introduction

Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative treatment for many malignant and nonmalignant hematologic disorders.¹⁻³ However, its success is hindered by graft-versus-host disease (GVHD), a potentially fatal complication deriving from alloreactive donor T cells attacking recipient tissues.⁴ Despite advances in the field of hematopoietic cell transplantation (HCT) and GVHD prophylaxis, acute GVHD (aGVHD) remains a major contributing factor to nonrelapse morbidity and mortality, affecting 30% to 50% of allo-HCT patients^{3,5}; it is also a leading cause of death after allo-HCT, with a mortality of nearly 20%.¹ Most of our knowledge about aGVHD pathophysiology derives from animal models.^{6,7} The complex and multifactorial nature of aGVHD, together with limited access to biological specimens, makes the study of the mechanisms involved in the development of human aGVHD particularly challenging. Although donor T cells are critical to the pathophysiology of acute and chronic GVHD,^{3,8-10} the precise mechanisms underlying their functions and the immune evasion leading to alloreactivity that occurs in allo-HCT recipients, despite immunosuppressive prophylaxis, are unclear.

Submitted 27 September 2019; accepted 7 July 2020; published online 20 August 2020. DOI 10.1182/bloodadvances.2019001032.

*E.L., D.M., and C.L. contributed equally to this work.

†G.S. and L.R. contributed equally to this work.

Data sharing requests should be sent to Lars Rogge (lars.rogge@pasteur.fr) or Gérard Socié (gerard.socie@aphp.fr).

The full-text version of this article contains a data supplement.

© 2020 by The American Society of Hematology

Here, we investigated the phenotypic and molecular characteristics of immune cells in patients after allo-HCT, as well as in their HLA-identical sibling donors, with the goal of defining the early immune parameters associated with the development of aGVHD. We analyzed 2 cohorts of donor-recipient pairs: a multicentric cohort from 13 French transplantation centers and a monocentric cohort from the Saint-Louis Hospital. We performed multiparameter immunophenotyping using spectral flow cytometry to define the frequencies of different T-cell subpopulations and gene-expression profiling of T-cell populations involved in aGVHD pathogenesis.

Our data demonstrate that the integrated analysis of the distribution of different immune cell subsets with spectral flow cytometry, together with gene-expression profiling, can contribute to elucidate the processes involved in the early immune reconstitution and aGVHD development in humans.

Materials and methods

Patients

Two independent cohorts of patients undergoing allogeneic HCT and their respective identical sibling donors were included in this study. We recently described the metabolomics serum analyses of these 2 cohorts.¹¹ Patient and donor characteristics are presented in Table 1. Cohort 1 includes 38 donor-recipient pairs for whom peripheral blood mononuclear cells (PBMCs) were provided by the CRYOSTEM biobank (<https://doi.org/10.25718/cryostem-collection/2018>). Cohort 2 includes 37 donor-recipient pairs for whom PBMCs samples were prospectively collected at Saint-Louis Hospital and cryopreserved. Blood samples from the donors were collected before the transplantation procedure, and samples from the recipients were collected at aGVHD onset or at day 90 post-HCT, for the patients who did not develop aGVHD. Details about the HCT procedure and aGVHD diagnosis are provided in supplemental Material and methods.

All patients gave their written consent for clinical research. This noninterventional research study, with no additional clinical procedure, was carried out in accordance with the Declaration of Helsinki. Data analyses were carried out using a database with all patient identifiers removed. This study was declared to the Commission National Informatique et Liberté and was approved by the local ethics committee and Institutional Review Board (IRB 00003835).

Spectral flow cytometry

Multicolor flow cytometric analysis was performed using a SP6800 Spectral Cell Analyzer (Sony Biotechnology), as described in detail in supplemental Material and methods. Cells were stained with the following anti-human monoclonal antibodies: anti-CD95, anti-CD3, anti-CD45RO, anti-CD8, anti-CD279 (PD1), anti-CD27, anti-CD196 (CCR6), anti-CD4, anti-CD45RA, and anti-CD122 (interleukin-2RB [IL-2RB]). A dump channel included anti-CD11c, anti-CD14, anti-CD19, and anti-CD34.

A second antibody panel, including intracellular markers, was used to analyze regulatory T cells (Tregs) with the following anti-human monoclonal antibodies: anti-CD25, anti-CD3, anti-CD4, anti-CD8, anti-CD27, anti-CD279 (PD1), anti-CD45RA, anti-CD278 (ICOS), and anti-CD127. After permeabilization, cells were stained with anti-FOXP3, anti-Ki67, and anti-CD152 (CTLA4).

Cell isolation and gene-expression analysis

Gene expression in sorted CD4⁺ and CD8⁺ T cells was assessed using the nCounter Human Immunology V2 codeset (NanoString Technologies), as described previously¹²⁻¹⁴ (see supplemental Material and methods for details).

Results

The T-cell compartment is skewed toward an effector memory phenotype early after HCT in patients without aGVHD

We evaluated the reconstitution patterns of different T-cell subsets at day 90 after transplantation in 2 independent cohorts of patients undergoing allo-HCT, as well as in their respective identical sibling donors. To avoid potential confounding effects related to aGVHD, only donor-recipient pairs without aGVHD were included in this analysis. Donor and patient characteristics and the study design are shown in Table 1 and supplemental Figure 1, respectively.

Cellular profiling of recipients 3 months post-HCT showed an incomplete reconstitution of the T-cell compartment, with decreased CD3⁺ T lymphocytes, compared with their respective donors. Within the CD3⁺ T-cell population, significantly decreased frequencies of CD4⁺ T cells and increased frequencies of CD8⁺ T cells were observed in both cohorts (Figure 1A; supplemental Figure 2A), resulting in an inversion of the normal CD4/CD8 ratio (Figure 1B; supplemental Figure 2B).

We next assessed whether early T-cell reconstitution was associated with imbalances in the distributions of naive and memory T-cell subsets in recipients after transplantation. Compared with their donors, recipients had a significant reduction in CD4⁺ and CD8⁺ naive T (T_{Naive}) cells, paralleled by an increase in effector memory T cells (T_{EMs}), in both cohorts (Figure 1C-D; supplemental Figure 2C). We also observed an increase in the terminally differentiated effector memory cells re-expressing CD45RA (T_{EMRA}) subset in recipients; it was more pronounced within the CD8⁺ population, but it was also present in the CD4⁺ T-cell compartment, in particular in cohort 2 (Figure 1D; supplemental Figure 2D). Analysis of Ki-67 expression revealed a strong increase in the proliferation of CD4⁺ and CD8⁺ T_{Naive} cell and memory T-cell subsets in recipients compared with their donors (Figure 1E; supplemental Figure 2D). A significant reduction in CD4⁺ and CD8⁺ T_{Naive} cells and an increase in effector CD4⁺ T cells were also observed in recipients at the onset of aGVHD compared with their donors in both cohorts (supplemental Figure 3).

Increased Treg proliferation and expression of functional markers in recipients after HCT

Given the importance of Tregs in GVHD prevention and HCT outcome,^{13,15,16} we investigated CD4⁺FOXP3⁺ Tregs in recipients without aGVHD compared with their sibling donors. Recipients showed a significant increase in CD4⁺FOXP3⁺ Tregs compared with their donors (Figure 2A), and the CD4⁺FOXP3⁺ Treg subset displayed increased frequency of Ki-67⁺ cells in the recipients early post-HCT compared with their donors (Figure 2B). Our data also revealed an increased frequency of Ki-67⁺ cells within Tregs compared with conventional CD4⁺ T cells (T_{convs}) in recipients following transplantation (Figure 2C, left panel). These data indicate that, in the lymphopenic environment of the host, T_{convs} and Tregs

Table 1. Patient and donor characteristics

Variable	Cohort 1 (multicentric)		Cohort 2 (monocentric)	
	Donors (n = 39)	Recipients (n = 38)	Donors (n = 42)	Recipients (n = 37)
Age, median (range), y	49.5 (14-65)	46 (17-68)	52.5 (15-67)	53 (22-67)
Sex				
Female	18 (46.1)	19 (50)	24 (57.1)	19 (51.4)
Male	20 (51.3)	19 (50)	18 (42.9)	18 (48.6)
Unknown	1 (2.6)	—	—	—
HLA-identical sibling donor, %		100		100
Graft type				
Bone marrow		11 (28.9)		3 (8.1)
Peripheral blood		26 (68.5)		34 (91.9)
Unknown		1 (2.6)		—
Sex match				
Male to male		10 (26.3)		7 (18.9)
Female to female		9 (23.7)		11 (29.7)
Male to female		10 (26.3)		8 (21.7)
Female to male		8 (21.1)		11 (29.7)
Unknown		1 (2.6)		—
Conditioning regimen				
Reduced intensity		17 (44.8)		32 (86.5)
Myeloablative		20 (52.6)		5 (13.5)
Unknown		1 (2.6)		—
Total body irradiation				
Yes		12 (31.6)		4 (10.8)
No		25 (65.8)		33 (89.2)
Unknown		1 (2.6)		—
Chimerism, median (range), %				
No GVHD		100 (86-100)		100 (60-100)
GVHD		100 (81-100)		100 (97-100)
Unknown		4 (10.5)		—
GVHD status				
GVHD		16 (42.1)		19 (51.4)
No GVHD		22 (57.9)		18 (48.6)
GVHD grade				
Grade 1		8 (50)		1 (5.3)
Grade 2		5 (31.1)		16 (84.1)
Grade 3		1 (6.3)		1 (5.3)
Grade 4		1 (6.3)		1 (5.3)
Unknown		1 (6.3)		—
Delay sample-graft, median (range), d				
Donors	−27 (−136 to 0)		−27 (−119 to −1)	
GVHD onset		29 (12-91)		36 (9-94)
No GVHD		91 (27-108)		90 (77-95)
GVHD prophylaxis				
CSA		7 (18.4)		2 (5.4)
CSA+MMF		8 (21.1)		26 (70.3)
CSA+MTX		22 (57.9)		8 (21.6)
None		0		1 (2.7)

Unless otherwise noted, data are n (%).

CMV, cytomegalovirus; CSA, cyclosporine A; D, donor; MMF, mycophenolate mofetil; MTX, methotrexate; R, recipient; —, none; −, negative; +, positive.

Table 1. (continued)

Variable	Cohort 1 (multicentric)		Cohort 2 (monocentric)	
	Donors (n = 39)	Recipients (n = 38)	Donors (n = 42)	Recipients (n = 37)
Unknown		1 (2.6)		—
Diagnosis				
Acute leukemia		17 (44.7)		13 (35.2)
Myeloproliferative neoplasm		3 (7.9)		8 (21.6)
Lymphoma		8 (21.1)		5 (13.5)
Myeloma		2 (5.3)		3 (8.1)
Myelodysplastic syndrome		4 (10.5)		2 (5.4)
Aplastic anemia		1 (2.6)		3 (8.1)
Chronic lymphoid leukemia		1 (2.6)		2 (5.4)
Other diagnosis		2 (5.3)		1 (2.7)
CMV serostatus				
Positive	22 (56.4)	20 (52.6)	23 (54.8)	29 (78.4)
Negative	16 (41)	16 (42.1)	19 (45.2)	8 (21.6)
Unknown	1 (2.6)	2 (5.3)	—	—
CMV status mismatch				
D+/R+		13 (34.2)		21 (56.8)
D-/R-		8 (21.1)		7 (18.9)
D+/R-		8 (21.1)		1 (2.7)
D-/R+		7 (18.4)		8 (21.6)

Unless otherwise noted, data are n (%).

CMV, cytomegalovirus; CSA, cyclosporine A; D, donor; MMF, mycophenolate mofetil; MTX, methotrexate; R, recipient; —, none; -, negative; +, positive.

undergo strong proliferation compared with healthy donors. The ratio of proliferating Tregs/Tconvs is higher in donors than in recipients (Figure 2C, right panel) because of the low proliferation of Tconvs in donors (Figure 1E). In recipients without aGVHD, an enrichment of Tregs expressing the functional markers CTLA4, ICOS, and PD-1 was also observed (Figure 2D), suggesting a counterbalancing mechanism to suppress alloreactivity and maintain tolerance in the proinflammatory environment of the host.

Major changes in the T-cell gene-expression profiles in patients without aGVHD compared with their sibling donors

To gain insight into the molecular changes associated with T-cell expansion early after HCT, we performed gene-expression profiling on sorted CD4⁺ and CD8⁺ T cells from donors before transplant and on day 90 post-HCT from recipients without aGVHD. Principal component analysis revealed a clear separation of the CD4⁺ and CD8⁺ T-cell gene-expression profiles, whereas samples from the 2 cohorts are homogeneously mixed, indicating the absence of “batch effects” between cohorts (supplemental Figure 4A). Principal component analysis also showed a clear separation between donor and recipient samples in CD4⁺ and CD8⁺ T-cell populations (supplemental Figure 4B).

Differential expression analysis showed that, in recipients, the majority of the genes analyzed are upregulated and only few genes are downregulated in the CD4⁺ and CD8⁺ T-cell populations. Importantly, a high degree of overlap of the differentially expressed genes between the 2 cohorts was observed, with changes in gene

expression occurring in the same direction (supplemental Figure 4C-D), demonstrating the robustness of our observations.

A modular transcriptional framework reveals altered biological pathways and molecular processes in T cells following HCT

To characterize the signaling pathways and the molecular functions that are altered in T cells after transplantation, we performed a pathway analysis on the T-cell gene-expression profiles from donors and recipients using Quantitative Set Analysis for Gene Expression (QuSAGE),¹⁷ which quantifies gene module activity as a shift in the mean differential expression of the individual genes included in the module. We designed 51 gene modules by grouping genes belonging to specific signaling pathways, associated with particular cellular phenotypes, or with specific cellular functions, according to Molecular Signatures Database annotations¹⁸ and based on current knowledge in the literature (supplemental Table 1), and compared T-cell gene-expression profiles in recipients without aGVHD and in their sibling donors.

In CD4⁺ T cells, QuSAGE revealed 46 modules with statistically significantly increased pathway activity in recipients compared with donors. Conversely, only few gene sets showed decreased pathway activity, and none of these reached statistical significance (Figure 3A).

Among the modules with the greatest increase in pathway activity in recipients and the lowest false discovery rate (FDR), were the “NLR inflammasome,” the “T helper 1 (Th1) profile,” and the “Memory”




Figure 1. T-cell compartment in recipients without aGVHD after HCT. Shown are results for donor/recipient couples without aGVHD from cohort 1. (A) Frequency of CD3⁺ T cells within the lymphocyte population (left panel) and frequencies of CD4⁺ (middle panel) and CD8⁺ (right panel) T cells within CD3⁺ T cells. (B) Ratio of CD4⁺

module, which includes genes enriched in memory T cells, followed by gene sets related to T-cell activation and cytotoxicity, interferon (IFN)-induced genes, genes associated with exhausted cells, and proapoptotic genes. The modules showing reduced pathway activity in recipients were the “Naive” module, regrouping genes upregulated in T_{Naive} cells, and the “WNT signaling” module (Figure 3A; supplemental Table 2).

QuSAGE of the gene-expression profiles of $CD8^+$ T cells (Figure 3B) showed that 43 gene modules were significantly different between donors and recipients: 40 had significantly increased pathway activity and 3 displayed significantly decreased pathway activity in recipients. Among the gene sets with the strongest and most significant increases in pathway activity, we found genes related to T-cell activation and coinhibitory molecules, IFN-induced genes, genes upregulated in memory T cells, proapoptotic genes, and genes upregulated in exhausted cells (“Exhaustion_up”). Interestingly, in $CD8^+$ T cells, we also observed modules displaying a significant reduction in pathway activity in recipients compared with donors. In particular, the “WNT signaling” module, the “Naive” module, and the “Exhaustion_down” module, including genes downregulated in exhausted T cells, had decreased pathway activity (Figure 3B; supplemental Table 3). Among the 40 gene modules upregulated in $CD8^+$ T cells, 38 were also upregulated in $CD4^+$ T cells, suggesting a large overlap in the signaling pathways affected by HCT in the 2 T-cell subsets (supplemental Figure 5).

The pathway activity of the gene modules showed a good correlation in the 2 cohorts (Figure 3C-D). Moreover, the ranking of the modules based on the pathway activity is similar (supplemental Figure 6A-B; supplemental Tables 2 through 5), indicating that the gene-expression signature associated with HCT and immune reconstitution is reproduced in 2 independent cohorts.

Closer inspection of individual genes within enriched modules showed that $CD4^+$ T cells in recipients displayed a gene-expression profile skewed toward the Th1 phenotype, with upregulation of genes such as *TBX21*, *IFNG*, and *CXCR3*. We also observed upregulation of genes involved in T-cell migration, such as the chemokine receptors *CX3CR1*, *CCR5*, *CXCR3*, *CCR2*, and *CCR6*, as well as many IFN-induced genes (Figure 3E).

Within the $CD8^+$ subset (Figure 3F), we noted upregulation of IFN-induced genes, as well as an enrichment of inhibitory receptors (*HAVCR2*, *CD160*, *PDCD1*, *CTLA4*, *LAG3*, *KLRD1*, *CD244*, *KLRG1*, *SLAMF7*) and genes associated with exhausted cells (*HAVCR2*, *BATF*, *CD160*, *PDCD1*, *CTLA4*, *EOMES*, *TBX21*, *LAG3*, *CASP3*, *CD244*, *KLRG1*, *SH2D1A*)¹⁹⁻²².

Consistent with the flow cytometry data showing a depletion of the T_{Naive} cell pool and an increase in cells with an effector memory phenotype after HCT (Figure 1D), we observed an enrichment of

many genes upregulated in memory cells (eg, *CD45RO*, *CD74*, *KLRG1*, *IL2RB*, *FAS*), whereas T_{Naive} cell-associated genes (eg, *CCR7*, *LEF1*, *TCF7*)²³⁻²⁷ were underrepresented in recipients (Figure 3E-F; supplemental Figure 7).

Cellular correlates of aGVHD onset in recipients following HCT

To identify potential “pathogenic” T-cell subsets associated with aGVHD onset, we next assessed whether the frequency of the different T-cell subsets and their proliferative status were altered in recipients developing aGVHD, before administration of any steroid therapy, compared with patients without aGVHD.

To increase the power of our analysis, we combined the samples from the 2 cohorts. We focused our analysis on recipients with grade 2-4 aGVHD to better identify changes associated with aGVHD. Compared with recipients without aGVHD ($n = 36$), at aGVHD onset, patients ($n = 22$) showed significantly increased frequencies of $CD4^+$ T cells and decreased $CD8^+$ T cells (supplemental Figure 8A), leading to a $CD4/CD8$ ratio generally >1 (supplemental Figure 8B). This contrasts with the posttransplant situation in patients without aGVHD, which is characterized by an inverted $CD4/CD8$ ratio (Figure 1B).

Analysis of the T_{Naive} cell and memory T-cell subsets revealed that, at aGVHD onset, recipients have significant increases in cells with a T memory stem cell-like ($T_{\text{SCM-like}}$) or a central memory T cell (T_{CM}) phenotype compared with recipients without aGVHD, whereas T_{EM} cells were decreased in the $CD4^+$ and $CD8^+$ compartments (supplemental Figure 8C). Increased cell proliferation was also observed at aGVHD onset in $CD4^+$ and $CD8^+$ compartments for T_{Naive} , T_{CM} , and T_{EM} subsets, as well as within the $CD4^+$ compartment for the T_{EMRA} subset (supplemental Figure 8D). Very similar results were obtained when the recipient/donor ratios of cell populations were compared for No GVHD couples vs aGVHD couples (Figure 4). In particular, we noted a significant expansion of $T_{\text{SCM-like}}$ relative to the donor sample in the $CD4$ and $CD8$ compartments in aGVHD couples (Figure 4).

T-cell transcriptional profiling at aGVHD onset reveals upregulation of proinflammatory mediators and downregulation of genes involved in immune regulation

The mechanisms underlying the immune escape and alloreactivity that occur, despite ongoing immunosuppression, and lead to aGVHD development in humans are still unclear. We performed gene-expression profiling on sorted $CD4^+$ and $CD8^+$ T cells from recipients without aGVHD and at aGVHD onset, before the start of steroid therapy. We used the same inclusion criteria as for the previous cellular profiling analysis (Figure 4; supplemental Figure 8D).

Figure 1. (continued) $CD8^+$ T cells in recipients (R) at day 90 post-HCT compared with their respective sibling donors (D). (C) Gating strategy used to identify naive and memory subsets within the $CD4^+$ and $CD8^+$ T-cell compartments in donors and recipients after transplantation by polychromatic flow cytometry. (D) Frequencies of T_{Naive} , $T_{\text{SCM-like}}$, T_{CM} , T_{EM} , and T_{EMRA} cells within the $CD4^+$ (upper panels) and $CD8^+$ (lower panels) T-cell compartments in recipients (R) at day 90 post-HCT compared with their respective sibling donors (D). (E) Frequency of proliferating Ki-67⁺ cells in total $CD4^+$ and $CD8^+$ T cells and in the different naive and memory subsets in $CD4^+$ (left panel) and $CD8^+$ (right panel) compartments in donors and recipients. The frequency of Ki-67⁺ cells is represented as the percentage of Ki-67-expressing cells within total $CD4^+$ or $CD8^+$ T cells and as the percentage Ki-67-expressing cells within the parent gate for T_{Naive} , T_{CM} , T_{EM} , and T_{EMRA} cell subsets. Horizontal lines indicate the median. *P* values were calculated using the Wilcoxon matched-pairs Student *t* test (donor vs respective recipient). Differences are considered significant for $P < .05$.




Figure 2. Treg homeostasis in recipients without aGVHD after HCT. Shown are results for donor/recipients couples without aGVHD from cohort 1. (A) Frequency of FOXP3⁺ cells within the CD4⁺ population in donors (D) and recipients (R) at day 90 post-HCT. (B) Frequencies of Ki67⁺, within the CD4⁺ FOXP3⁺ Treg population, in donors (D) and recipients (R) at day 90 post-HCT. (C) Frequency of proliferating (Ki67⁺) cells within the CD4⁺FOXP3⁺ Treg and CD4⁺FOXP3⁻ Tconv populations in donors (D) and recipients (R) (left panel) and ratios of proliferating (Ki67⁺) Treg/Tconv in donors (D) and recipients (R) at day 90 post-HCT (right panel). (D) Frequencies of CTLA4⁺, ICOS⁺, and PD1⁺ cells within the CD4⁺FOXP3⁺ Treg population in donors (D) and recipients (R) at day 90 post-HCT. Horizontal lines indicate the median. *P* values were calculated using a Wilcoxon matched-pairs Student *t* test or a Mann-Whitney *U* test. Differences are considered significant for *P* < .05.

Gene-expression profiles of CD4⁺ T cells showed differential expression of 18 genes in patients with aGVHD compared with No GVHD recipients (FDR < 0.05). Of these, 2 were expressed at higher levels and 16 were expressed at lower levels in patients with aGVHD (Figure 5A). QuSAGE revealed 6 modules with significantly decreased pathway activity at aGVHD onset. Interestingly, genes associated with “transforming growth factor- β (TGF- β) signaling” were downregulated most significantly (Figure 5B; supplemental Table 6). Closer inspection of the differentially expressed

transcripts within this module showed that CD4⁺ T cells from recipients at aGVHD onset had significantly lower expression levels of genes encoding *TGFBR1*, *SMAD3*, and *IGF2R* compared with the No GVHD group (Figure 5C). In contrast, we noticed increased levels of genes involved in the NF- κ B signaling pathway (eg, *BCL10* and *BCL3*) at aGVHD onset. Expression of *PSMD7*, encoding a component of the 26S proteasome, and of *ICOS* (Figure 5D), a member of the CD28 superfamily, induced in CD4⁺ and CD8⁺ T cells during T-cell activation,²⁸ was also higher at aGVHD onset.




Figure 3. Molecular signature of T cells in recipients without aGVHD after HCT compared with their donors. QuSAGE of CD4⁺ (A) and CD8⁺ (B) T-cell gene expression profiles in recipients at day 90 post-HCT compared with their respective donors before transplant in cohort 1. For each pathway, the mean fold change and the 95% confidence intervals are plotted and color-coded according to their FDR-corrected *P* values compared with 0. Red and green bars indicate a statistically significant increased or decreased pathway activity, respectively, in recipients compared with donors. Correlation between cohorts 1 and 2 for QuSAGE in CD4⁺ (C) and CD8⁺ (D) T cells. Red dots correspond to modules significantly enriched (FDR ≤ 0.05) in both cohorts, blue dots correspond to modules enriched in only 1 cohort, and black dots




Figure 3. (continued) correspond to modules not enriched. The concordance correlation coefficient (CCC) is displayed to quantify the reproducibility of the results between the 2 cohorts. Relative gene-expression levels of genes in selected enriched modules in recipients at day 90 post-HCT compared with their respective donors before transplant in cohort 1 in CD4⁺ (E) and CD8⁺ (F) T cells. In the heat maps, columns represent samples and are ordered by hierarchical clustering, whereas rows represent genes and are ranked by fold change. Yellow indicates high levels of expression, and blue indicates low levels of expression. Ag, antigen; CTL, cytotoxic T lymphocyte; MHC, major histocompatibility complex; TCR, T-cell receptor; TF, transcription factor; TGF, transforming growth factor; TLR, Toll-like receptor; TNF, tumor necrosis factor.

CD8⁺ T cells from recipients at aGVHD onset showed differential expression of 134 genes compared with recipients without aGVHD (FDR < 0.05): higher expression levels for 23 genes and lower levels for 111 transcripts at aGVHD onset (Figure 6A). Among the transcripts with higher levels in patients with aGVHD were genes involved in NF-κB signaling (*NFKB1*, *BCL3*) and the negative regulator *NFKBIA*. Similarly to CD4⁺ T cells, *PSMD7* and *ICOS* showed higher expression in patients with aGVHD. In addition, CD8⁺ T cells displayed increased expression of the costimulatory molecule *CD28*, the inflammatory mediator *MIF*, and the glycolytic enzyme *GAPDH* (Figure 6B). The switch from oxidative phosphorylation to aerobic glycolysis is a hallmark of T-cell activation, and aerobic glycolysis was shown to facilitate full effector status and IFN-γ production in T cells.²⁹

QuSAGE identified 24 gene modules that were significantly different between patients with and without aGVHD (Figure 6C; supplemental Table 7). Of these, 23 modules had significantly decreased pathway activity, and only 1 module had significantly higher activity, at aGVHD onset. The latter is the “NF-κB-TFs” module, which includes the NF-κB transcription factors *NFKB1*, *NFKB2*, *RELA*, and *RELB*, suggesting an important role for the NF-κB signaling pathway in alloreactive T cells mediating aGVHD in humans.

Similarly to CD4⁺ T cells, the “TGF-β signaling” module was most significantly downregulated in CD8⁺ T cells at aGVHD onset (Figure 6C; supplemental Table 7; *P* = .00005; FDR = 0.002). We also observed the “Coinhibitory” and “Anti-inflammatory” modules among those with significantly lower pathway activity. Transcript levels of representative genes belonging to these modules are shown in Figure 6D. We found downregulation of genes involved in TGF-β signaling (*TGFBR2*, *SMAD3*, *IGF2R*), as well as genes encoding inhibitory receptors (*LAIR1*, *BTLA*, *KLRG1*)^{30–33} and molecules mediating immunosuppressive signals (*IL10RA*),³⁴ suggesting that decreased expression of genes involved in regulation and dampening of immune responses may be implicated in the development of aGVHD.

Discussion

In this study, we investigated the cellular and molecular mechanisms underlying aGVHD development or the absence of significant aGVHD at 3 months posttransplant in 2 cohorts of patients undergoing allo-HCT from their HLA-identical sibling donors. We provide one of the first transcriptional analyses of sorted CD4⁺ and CD8⁺ T cells showing striking differences between healthy donors and recipients without aGVHD, as well as noticeable differences in patients with and without aGVHD. To the best of our knowledge, an analysis of T-cell gene-expression profiles at steady-state in healthy donors vs allogeneic recipients without aGVHD in the same system has not been performed.

Although previous work in an experimental mouse model has demonstrated that naive cells are more likely to respond to weak- or low-affinity antigens in lymphopenic conditions,³⁵ and that homeostatic proliferation of T_{Naive} cells is associated with the acquisition of a memory-like phenotype in these conditions,³⁶ data on early immune reconstitution are scarce. The largest cohort analyzed so far,³⁷ included only the simultaneous study of 5 surface T-cell markers; most studies aiming to analyze T-cell reconstitution posttransplantation were performed at a later time point.^{3,8,16,38}

The simultaneous analysis of multiple surface and intracellular markers of Tregs and Tconvs was facilitated by the use of spectral flow cytometry, which allowed the analysis of limited numbers of cells for each patient sample. The introduction of mass cytometry would allow an even more comprehensive analysis of immune cells³⁸; however, this technology was not accessible when this study was designed.

In patients without aGVHD, we found an incomplete reconstitution of the T-cell compartment after transplant with a bias toward an effector/memory phenotype and a depletion of T_{Naive} cells compared with their sibling donors. We noted increased proliferation of all CD4⁺ and CD8⁺ T_{Naive} and T memory subsets analyzed in recipients compared with donors. In particular, we found high proliferation of the Treg compartment, confirming our previous results and those from other investigators.^{13,16} Increased T-cell proliferation in recipients after HCT could be driven by increased availability of the homeostatic cytokines IL-7 and IL-15 after transplantation,^{16,39,40} as well as stimulation by the host alloantigens. Tregs in recipients may also acquire increased activity, as shown by increased expression of CTLA4 and ICOS, molecules of key importance for their suppressive functions.^{41,42}

To investigate the molecular mechanisms underlying T-cell expansion after HCT, we analyzed gene expression in sorted CD4⁺ and CD8⁺ T cells from donors before transplant and from patients without aGVHD on day 90 post-HCT, using nCounter assays. This approach is well adapted to the analysis of the low T-cell numbers recovered, in particular in recipients post-HCT, and is very robust because no enzymatic reaction or polymerase chain reaction amplification is needed.^{14,43} Our gene-expression analysis revealed that HCT is associated with major transcriptional changes in CD4⁺ and CD8⁺ T cells in recipients compared with their donors.

We found that donor T cells react to the environment of the host by acquiring an activated phenotype with upregulation of genes associated with T-cell activation and its regulation, adhesion, and migration, as well as effector functions, especially linked to a Th1 cell profile and cytotoxicity. Consistent with our flow cytometry data, we observed an enrichment of many genes reported to be expressed in memory T cells and an underrepresentation of genes associated with T_{Naive} cells. The increased activation may be associated with T-cell dysfunction, as suggested by the increased expression of proapoptotic genes and genes upregulated in exhausted cells.

Analysis of the different T_{Naive} cell and memory T-cell subsets in recipients, using spectral flow cytometry, revealed that patients had a significant increase in CD4⁺ and CD8⁺ cells with a T_{SCM}-like phenotype at aGVHD onset compared with recipients without aGVHD. T memory stem cells (T_{SCM}) have been shown to sustain alloreactive T cells mediating GVHD upon serial transplantation into allogeneic hosts in mice.²⁷ Gattinoni and colleagues reported the identification of T_{SCM} in humans,⁴⁴ but an association between this cell subset and human aGVHD has not been described. The ability of T_{SCM} to sustain the generation of all memory and effector T-cell subsets while maintaining their own pool through self-renewal has important implications for aGVHD pathophysiology.^{27,44,45} T_{SCM} cells could represent a cellular reservoir for alloreactive T cells in recipients developing GVHD, sustaining the production of alloreactive donor T cells in the presence of persistent antigens in hosts. Further investigation including additional markers for a more




Figure 4. Cellular correlates of aGVHD onset. (A) Ratios of the frequency of $CD3^+$ T cells within lymphocytes (left panel), $CD4^+$ T cells within $CD3^+$ T cells (middle panel), and $CD8^+$ T cells within $CD3^+$ T cells (right panel) between recipients and donors (R/D) in aGVHD vs No aGVHD couples. (B) Ratios of the frequency of T_{naive} , $T_{SCM-like}$, T_{cm} , T_{EM} , and T_{EMRA} cells within $CD4^+$ cells (upper panels) and $CD8^+$ cells (lower panels) between R/D in aGVHD vs No aGVHD couples. Horizontal lines indicate the median. For this analysis, samples from the 2 cohorts were pooled. All recipients without aGVHD or with grade ≥ 2 aGVHD were included in the analysis (No GVHD, $n = 36$; GVHD, $n = 22$). P values were calculated using the Mann-Whitney U test; differences are considered significant for $P < .05$.

detailed phenotypic characterization, together with functional studies, may elucidate the role of this cell subset in aGVHD.

To investigate genes and pathways involved in aGVHD pathogenesis, we performed gene-expression profiling of sorted $CD4^+$ and $CD8^+$ T cells from recipients without aGVHD and at aGVHD onset, before the start of steroid therapy. With regard to the cellular profiling, we focused this analysis on recipients with grades 2-4 aGVHD.

Perreault et al performed $CD4^+$ and $CD8^+$ T-cell gene-expression profiling of donors and found that TGF- β signaling and genes implicated in cell proliferation characterized “dangerous” donors with regard to the recipient’s risk for developing chronic GVHD.⁴⁶ Only a few other studies in small cohorts have analyzed the gene-expression profile associated with aGVHD in humans.⁴⁷⁻⁴⁹ These studies used microarray analyses of PBMCs^{47,49} or microbead-enriched immune cell subpopulations⁴⁸; the sets of genes that were up- or downregulated before or at aGVHD onset in the different studies are not consistent, possibly because of the heterogeneity of the patient populations.

Our analysis of signaling pathways associated with aGVHD onset also showed downregulation of genes involved in TGF- β signaling,⁴⁶ whereas genes involved in the NF- κ B signaling pathway, which plays a central role in mediating T-cell receptor signaling and T-cell activation and differentiation,⁵⁰ were upregulated at aGVHD onset. These data support an important role for the NF- κ B pathway in alloreactive $CD4^+$ and $CD8^+$ T cells mediating human aGVHD. Consistently, inhibition of NF- κ B was shown to protect mice from lethal GVHD.⁵¹

We noted that the proteasome subunit *PSMD7* is expressed at higher levels in $CD4^+$ and $CD8^+$ T cells at aGVHD onset. Proteasome activity has been shown to induce memory at the expense of effector T-cell differentiation in a mouse model,⁵² consistent with the downregulation of the gene module “CTL cytotoxicity” that we observed at aGVHD onset in $CD8^+$ T cells. These data are further corroborated by the higher frequencies of $T_{SCM-like}$ and T_{CM} subsets and the lower frequencies of T_{EM} s at aGVHD onset. Together, these findings may suggest an important role for memory T-cell subsets in aGVHD pathogenesis.




Figure 5. CD4⁺ T-cell gene-expression signature at aGVHD onset. For this analysis, samples from the 2 cohorts were pooled. All recipients without aGVHD or with grade ≥ 2 aGVHD were included in the analysis (No GVHD, n = 35; GVHD, n = 24). (A) Gene-expression profiles of CD4⁺ T cells from 24 patients at aGVHD onset compared with 35 patients without aGVHD in cohorts 1 and 2. Orange and light blue dots represent transcripts that were significantly up- and downregulated in recipients at aGVHD onset compared with No GVHD recipients, respectively, with FDR < 0.05. P values were calculated using an unpaired Student t test. Adjusted P values (FDR) were calculated using the Benjamini-Hochberg method to correct for multiple comparisons. (B) Results of QuSAGE conducted on CD4⁺ T-cell gene-expression profiles from aGVHD and No GVHD recipients. Plotted is the negative logarithm to the base 10 of the P values for the 6 modules with significantly different pathway activity (FDR < 0.05) at GVHD onset compared with No GVHD recipients. (C) Transcript levels of *TGFB1*, *SMAD3*, and *IGF2R* in CD4⁺ T cells from recipients without aGVHD (No GVHD) and at aGVHD onset (GVHD). These genes showed decreased expression at aGVHD onset compared with recipients without GVHD ($P < .05$; FDR < 0.1). (D) Transcript levels of *BCL3*, *BCL10*, *ICOS*, and *PSMD7* in CD4⁺ T cells from recipients without aGVHD and at aGVHD onset. These genes showed increased expression at aGVHD onset compared with recipients without aGVHD ($P < .05$; FDR < 0.1). P values were calculated using an unpaired Student t test. Adjusted P values (FDR) were calculated using the Benjamini-Hochberg method to correct for multiple comparisons. Nominal P values are shown in panels B and D.

Finally, we found higher expression of *ICOS* in CD4⁺ and CD8⁺ T cells at aGVHD onset. This observation may be of particular interest, because previous studies in mouse models have

established that using neutralizing anti-*ICOS* antibodies to block *ICOS* significantly ameliorated GVHD in multiple strain combinations, even when used in a therapeutic setting (injection 5 days after




Figure 6. CD8⁺ T-cell gene-expression signature at aGVHD onset. For this analysis, samples from the 2 cohorts were pooled. All recipients without aGVHD or with aGVHD grade ≥ 2 were included in the analysis (No GVHD, n = 36; GVHD, n = 22). (A) Gene-expression profiles of CD8⁺ T cells from 22 patients at aGVHD onset compared with 36 patients without aGVHD in cohorts 1 and 2. Orange and light blue dots represent transcripts that were significantly up- or downregulated in recipients at aGVHD onset compared with No GVHD recipients, respectively, with FDR < 0.05. P values were calculated using an unpaired Student t test. Adjusted P values (FDR) were calculated using the Benjamini-Hochberg method to correct for multiple comparisons. (B) Transcript levels of *NFKB1*, *BCL3*, *NFKBIA*, *ICOS*, *CD28*, *MIF*, and *GAPDH* in CD8⁺ T cells from recipients without aGVHD and at aGVHD onset. These genes showed increased expression at aGVHD onset compared with recipients without GVHD ($P < .05$; FDR < 0.05). (C) QuSAGE of CD8⁺ T-cell gene-expression profiles in recipients at aGVHD onset compared with recipients without aGVHD from cohorts 1 and 2. For each pathway, the mean fold change and the 95% confidence intervals are plotted and color-coded according to their FDR-corrected P values compared with 0. Red and green bars indicate a statistically significant increased or decreased pathway activity, respectively, in recipients at aGVHD onset compared with recipients without aGVHD. (D) Transcript levels of *TGFB2*, *SMAD3*, *IGFB2*, *LAIR1*, *BTLA4*, *KLRG1*, and *IL10RA* in CD8⁺ T cells from recipients at aGVHD onset compared with recipients without aGVHD. These genes showed decreased expression at aGVHD onset compared with recipients without aGVHD ($P < .05$; FDR < 0.05). P values were calculated using an unpaired Student t test. Adjusted P values (FDR) were calculated using the Benjamini-Hochberg method to correct for multiple comparisons. Nominal P values are shown in panels C and D. Tfh, T follicular helper cell.

transplantation).^{53,54} More recently, Burlion and colleagues demonstrated that blockade of human ICOS prevented GVHD in a xenogeneic GVHD model, in which human PBMCs were transferred into irradiated immunocompromised NOD.SCID. $\gamma c^{-/-}$

mice.⁵⁵ Importantly, ICOS blockade did not reduce the graft-versus-leukemia effect. Higher *ICOS* expression in T cells at aGVHD onset may provide additional evidence to explore ICOS blockade as a therapeutic strategy for aGVHD treatment.

This study has some limitations. One issue is how to compare human immune dysregulation at disease onset. We designed the study to be able to compare our findings at disease onset with 2 “comparators”: the immune system at “baseline” (ie, data recovered from the donor samples) and recipients without aGVHD at day 90. Comparing patients at the onset of aGVHD with those without aGVHD leads to intrinsic differences between groups of patients (supplemental Figure 1B). Furthermore, we acknowledge that using day-90 profiles in patients without aGVHD as a comparator for profiles of patients with aGVHD at disease onset can be criticized. However, other comparators, such as patients without aGVHD at the same mean elapse time as those with aGVHD, was not chosen because these “non-GVHD” controls may eventually develop GVHD a few days after sampling at a time during which the processes were already ongoing. This was a discovery-driven study; future studies may address these potential confounders. In particular, future studies should be designed to include prospective phenotypic and molecular evaluation of T-cell subsets (including T_{SCM}) at different time points (including disease onset) in all patients, considering for analyses patients classified as “no GVHD, active GVHD, or before the onset of GVHD” at a given time point. Other transplant-related factors (including the heterogeneity of GVHD prophylaxes) may have influenced our results, in particular in patients without aGVHD. This exploratory study was not designed or powered to evaluate these factors in multivariate analyses (which better reflect the multifactorial nature of allo-HCT).

However, this is the first study to integrate spectral flow cytometry and gene-expression profiling in the investigation of aGVHD at disease onset. Our data suggest that the integrated analysis of the distribution of different immune cell subsets with flow cytometry, together with gene-expression profiling, can contribute to the elucidation of the processes involved in aGVHD development in humans. Assessment of other potentially interesting cell subsets (eg, B-cell subsets, innate lymphoid cells), as well as single-cell gene expression and epigenetics analyses, will be of particular importance for future investigations to elucidate disease processes in humans and guide novel strategies for the prevention and treatment of GVHD.

Acknowledgments

The authors thank all the members of the CRYOSTEM Consortium and the Francophone Society of Marrow Transplantations and

Cellular Therapy for providing patient samples used in this study, as well as the Center for Translational Science/Cytometry Biomarkers Unit of Technology and Service (Institut Pasteur) for support in conducting this study.

This work was supported by grants from the Agence Nationale de la Recherche (ANR-PRTS 13002), the Institut National du Cancer (INCa 2014-1-PL BIO-07-IP-1), and the Direction Générale de l'Offre de Soins, as well as by institutional funds from Institut Pasteur. E.L. was supported by a grant from the Université Paris Diderot and the Ministère de la Recherche. G.S. received a research grant from ALEXION Pharmaceuticals. The CRYOSTEM project is supported by a grant from the Institut National du Cancer and the Agence Nationale de la Recherche and is under the auspices of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Authorship

Contribution: E.L. and C.L. performed experiments; E.L., C.L., D.M., E.B., and L.R. collected and analyzed the data; H.V. performed bioinformatics analyses; E.L., C.L., and H.V. prepared the figures; D.M. and G.S. had overall medical oversight, provided patient samples and clinical data, performed clinical data analysis, and revised the manuscript; R.P.d.L. coordinated the CRYOSTEM Consortium and provided access to samples from cohort 1; E.L., E.B., G.S., and L.R. wrote the manuscript; L.R. and G.S. conceived the project, secured funding, and supervised the work; and all authors approved the final version of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

A complete list of the members of the CRYOSTEM Consortium appears in the supplemental Data.

ORCID profiles: D.M., 0000-0003-4553-3065; C.L., 0000-0003-3525-0854; H.V., 0000-0003-3980-4463; E.B., 0000-0001-6612-8881; G.S., 0000-0002-2114-7533; L.R., 0000-0003-1262-9204.

Correspondence: Lars Rogge, Immunoregulation Unit, Department of Immunology, Institut Pasteur, 25 Rue du Docteur Roux, 75015 Paris, France; e-mail: lars.rogge@pasteur.fr; and Gérard Socié, Service d'Hématologie Greffe, Hôpital Saint Louis, 1 Av Claude Vellefaux, 75010 Paris, France; e-mail: gerard.socie@aphp.fr.

References

1. McDonald-Hyman C, Turka LA, Blazar BR. Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. *Sci Transl Med*. 2015;7(280):280rv2.
2. Socié G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside. *Blood*. 2009;114(20):4327-4336.
3. Zeiser R, Blazar BR. Acute graft-versus-host disease—biologic process, prevention, and therapy. *N Engl J Med*. 2017;377(22):2167-2179.
4. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. *Annu Rev Immunol*. 2007;25(1):139-170.
5. Sung AD, Chao NJ. Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. *Stem Cells Transl Med*. 2013;2(1):25-32.
6. Schroeder MA, DiPersio JF. Mouse models of graft-versus-host disease: advances and limitations. *Dis Model Mech*. 2011;4(3):318-333.
7. Zeiser R, Blazar BR. Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? [published correction appears in *Blood*. 2016;128(10):1441]. *Blood*. 2016;127(25):3117-3126.
8. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. *Blood*. 2010;115(19):3861-3868.

9. Thangavelu G, Blazar BR. Achievement of tolerance induction to prevent acute graft-vs.-host disease. *Front Immunol.* 2019;10:309.
10. Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. *N Engl J Med.* 2017;377(26):2565-2579.
11. Michonneau D, Latis E, Curis E, et al. Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites. *Nat Commun.* 2019;10(1):5695.
12. Coffre M, Roumier M, Rybczynska M, et al. Combinatorial control of Th17 and Th1 cell functions by genetic variations in genes associated with the interleukin-23 signaling pathway in spondyloarthritis. *Arthritis Rheum.* 2013;65(6):1510-1521.
13. Dong S, Maiella S, Xhaard A, et al. Multiparameter single-cell profiling of human CD4⁺FOXP3⁺ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease. *Blood.* 2013;122(10):1802-1812.
14. Yahia-Cherbal H, Rybczynska M, Lovecchio D, et al. NFAT primes the human RORC locus for ROR γ t expression in CD4⁺ T cells [published correction appears in *Nat Commun.* 2019;10(1):5450]. *Nat Commun.* 2019;10(1):4698.
15. Edinger M, Hoffmann P, Ermann J, et al. CD4⁺CD25⁺ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. *Nat Med.* 2003;9(9):1144-1150.
16. Matsuoka K, Kim HT, McDonough S, et al. Altered regulatory T cell homeostasis in patients with CD4⁺ lymphopenia following allogeneic hematopoietic stem cell transplantation. *J Clin Invest.* 2010;120(5):1479-1493.
17. Yaari G, Bolen CR, Thakar J, Kleinstein SH. Quantitative set analysis for gene expression: a method to quantify gene set differential expression including gene-gene correlations. *Nucleic Acids Res.* 2013;41(18):e170.
18. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. *Bioinformatics.* 2011; 27(12):1739-1740.
19. Crawford A, Angelosanto JM, Kao C, et al. Molecular and transcriptional basis of CD4⁺ T cell dysfunction during chronic infection. *Immunity.* 2014;40(2): 289-302.
20. Man K, Gabriel SS, Liao Y, et al. Transcription factor IRF4 promotes CD8⁽⁺⁾ T cell exhaustion and limits the development of memory-like T cells during chronic infection. *Immunity.* 2017;47(6):1129-1141.e5.
21. Thorp EB, Stehlik C, Ansari MJ. T-cell exhaustion in allograft rejection and tolerance. *Curr Opin Organ Transplant.* 2015;20(1):37-42.
22. Wherry EJ. T cell exhaustion. *Nat Immunol.* 2011;12(6):492-499.
23. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. *Annu Rev Immunol.* 2014; 32(1):659-702.
24. Weng NP, Araki Y, Subedi K. The molecular basis of the memory T cell response: differential gene expression and its epigenetic regulation. *Nat Rev Immunol.* 2012;12(4):306-315.
25. Willinger T, Freeman T, Hasegawa H, McMichael AJ, Callan MF. Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets. *J Immunol.* 2005;175(9):5895-5903.
26. Willinger T, Freeman T, Herbert M, Hasegawa H, McMichael AJ, Callan MF. Human naive CD8 T cells down-regulate expression of the WNT pathway transcription factors lymphoid enhancer binding factor 1 and transcription factor 7 (T cell factor-1) following antigen encounter in vitro and in vivo. *J Immunol.* 2006;176(3):1439-1446.
27. Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Host-reactive CD8⁺ memory stem cells in graft-versus-host disease. *Nat Med.* 2005;11(12):1299-1305.
28. Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. *Nature.* 1999;397(6716): 263-266.
29. Chang CH, Curtis JD, Maggi LB Jr., et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. *Cell.* 2013;153(6):1239-1251.
30. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition [published correction appears in *Nat Rev Immunol.* 2013;13(7):542]. *Nat Rev Immunol.* 2013;13(4):227-242.
31. Kang X, Kim J, Deng M, et al. Inhibitory leukocyte immunoglobulin-like receptors: immune checkpoint proteins and tumor sustaining factors. *Cell Cycle.* 2016;15(1):25-40.
32. Murphy KM, Nelson CA, Sedý JR. Balancing co-stimulation and inhibition with BTLA and HVEM. *Nat Rev Immunol.* 2006;6(9):671-681.
33. Odorizzi PM, Wherry EJ. Inhibitory receptors on lymphocytes: insights from infections. *J Immunol.* 2012;188(7):2957-2965.
34. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. *Nat Rev Immunol.* 2010;10(3):170-181.
35. Goldrath AW, Bevan MJ. Low-affinity ligands for the TCR drive proliferation of mature CD8⁺ T cells in lymphopenic hosts. *Immunity.* 1999;11(2): 183-190.
36. Tchao NK, Turka LA. Lymphodepletion and homeostatic proliferation: implications for transplantation. *Am J Transplant.* 2012;12(5):1079-1090.
37. Podgorny PJ, Liu Y, Dharmani-Khan P, et al. Immune cell subset counts associated with graft-versus-host disease. *Biol Blood Marrow Transplant.* 2014; 20(4):450-462.
38. Stern L, McGuire H, Avdic S, et al. Mass cytometry for the assessment of immune reconstitution after hematopoietic stem cell transplantation. *Front Immunol.* 2018;9:1672.
39. Thiant S, Moutouou MM, Leboeuf D, Guimond M. Homeostatic cytokines in immune reconstitution and graft-versus-host disease. *Cytokine.* 2016;82:24-32.
40. De Bock M, Fillet M, Hannon M, et al. Kinetics of IL-7 and IL-15 levels after allogeneic peripheral blood stem cell transplantation following nonmyeloablative conditioning. *PLoS One.* 2013;8(2):e55876.

41. Ito T, Hanabuchi S, Wang YH, et al. Two functional subsets of FOXP3⁺ regulatory T cells in human thymus and periphery. *Immunity*. 2008;28(6): 870-880.
42. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3⁺ regulatory T cell function. *Science*. 2008;322(5899):271-275.
43. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. *Nat Biotechnol*. 2008;26(3): 317-325.
44. Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. *Nat Med*. 2011;17(10):1290-1297.
45. Gattinoni L, Speiser DE, Lichterfeld M, Bonini C. T memory stem cells in health and disease. *Nat Med*. 2017;23(1):18-27.
46. Baron C, Somogyi R, Greller LD, et al. Prediction of graft-versus-host disease in humans by donor gene-expression profiling. *PLoS Med*. 2007;4(1):e23.
47. Buzzeo MP, Yang J, Casella G, Reddy V. A preliminary gene expression profile of acute graft-versus-host disease. *Cell Transplant*. 2008;17(5):489-494.
48. Takahashi N, Sato N, Takahashi S, Tojo A. Gene-expression profiles of peripheral blood mononuclear cell subpopulations in acute graft-vs-host disease following cord blood transplantation. *Exp Hematol*. 2008;36(12):1760-1770.
49. Verner J, Kabathova J, Tomancova A, et al. Gene expression profiling of acute graft-vs-host disease after hematopoietic stem cell transplantation. *Exp Hematol*. 2012;40(11):899-905.e5.
50. Oh H, Ghosh S. NF- κ B: roles and regulation in different CD4(+) T-cell subsets. *Immunol Rev*. 2013;252(1):41-51.
51. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. *Blood*. 2006;107(2):827-834.
52. Widjaja CE, Olvera JG, Metz PJ, et al. Proteasome activity regulates CD8⁺ T lymphocyte metabolism and fate specification. *J Clin Invest*. 2017;127(10): 3609-3623.
53. Li J, Semple K, Suh WK, et al. Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice. *Biol Blood Marrow Transplant*. 2011;17(7):962-969.
54. Taylor PA, Panoskaltis-Mortari A, Freeman GJ, et al. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). *Blood*. 2005;105(8):3372-3380.
55. Burlion A, Brunel S, Petit NY, Olive D, Marodon G. Targeting the human T-cell inducible costimulator molecule with a monoclonal antibody prevents graft-vs-host disease and preserves graft vs leukemia in a xenograft murine model. *Front Immunol*. 2017;8:756.